plaque-forming units (pfu)/ml] encoding either the iNOS gene or the ␤-galactosidase reporter gene. Twenty-four hours after transduction, Western blot analysis demonstrated expression of iNOS protein only in iNOS (10 9 pfu/ml)-transduced arteries. Immunohistochemical analysis localized iNOS expression predominantly in adventitia. Vascular reactivity of isolated basilar arteries was studied by isometric force recording. Concentration-response curves to UTP (10 Ϫ9 -10 Ϫ3 M) and diethylaminodiazen-1-ium-1,2-dioate (10 Ϫ10 -10 Ϫ5 M) were significantly shifted to the right in iNOS gene (10 9 pfu/ml)-transduced rings compared with control and ␤-galactosidase-transduced rings (P Ͻ 0.05, n ϭ 5-6). Endothelium-dependent relaxation to bradykinin was significantly attenuated in iNOS-transduced rings (P Ͻ 0.001, n ϭ 8). The basal level of cGMP and superoxide anion (O 2 Ϫ ⅐) production were elevated in iNOS-transduced rings (P Ͻ 0.05, n ϭ 7 for cGMP; P Ͻ 0.01, n ϭ 6-9 for O 2 Ϫ ⅐ production). Our results suggest that expression of recombinant iNOS in cerebral arteries reduces vasomotor reactivity to both vasoconstrictor and vasodilator agonists. Attenuation of contractions is most likely due to functional antagonism between UTP and cGMP. Reduction of endothelium-dependent relaxation to bradykinin appears to be mediated in part by reduced reactivity of smooth muscle cells to NO. adventitia; bradykinin; nitric oxide; superoxide anion; inducible nitric oxide synthase NITRIC OXIDE (NO) synthesized by enzymatic activity of endothelial NO synthase (eNOS) is a key mediator of smooth muscle relaxation in the normal blood vessels (22) . During inflammation, inducible NO synthase (iNOS) is expressed in the vessel wall, including the adventitia (17, 36) , and is associated with attenuation of vasoconstriction and vasodilatation (3, 26) . A more recent study (8) has demonstrated that ex vivo iNOS gene transfer to normal carotid arteries caused attenuation of vasoconstriction mediated by activation of ␣-adrenergic and thromboxane A 2 receptors. Interestingly, in vivo adenovirus-mediated iNOS expression also attenuated endothelium-dependent relaxations (8) .
The role of iNOS expression in pathogenesis of vascular diseases is not fully understood. Both beneficial and detrimental effects of iNOS expression on vascular homeostasis have been reported (6, 12, 14, 18, 27) . A number of previous studies (13, 32) have demonstrated that vasomotor reactivity of cerebral arteries is different from reactivity of the peripheral arteries. Effects of recombinant iNOS expression on vasomotor function of cerebral arteries have not been studied. Furthermore, iNOS appears to play an important role in pathogenesis of cerebrovascular diseases including stroke (11) . Thus the present study was designed to characterize the effect of recombinant iNOS expression in cerebral arteries. We hypothesized that increased expression of iNOS may have inhibitory effect on vasoconstrictor and vasodilator function of cerebral arteries.
MATERIALS AND METHODS

Adenoviral vectors.
An E1-and E3-deleted adenoviral vector carrying human iNOS cDNA (AdiNOS) was designed and constructed as previously described (27, 28 ). An E1-and E3-deleted adenoviral vector carrying the ␤-galactosidase (␤-Gal) gene (AdLacZ) was used in all gene transfer experiments as a control, which was designed and constructed as previously described (28, 34) . The titer of AdiNOS preparation was ϳ5 ϫ 10 11 plaque-forming units (pfu)/ml, whereas the AdLacZ titer was ϳ2 ϫ 10 12 pfu/ml. Gene transfer. All procedures were in accordance with the Institutional Animal Care and Use Committee guidelines of Mayo Clinic. Basilar arteries were taken from mongrel dogs (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) Rings were randomly assigned for gene transfer and were transduced with adenoviral vectors (10 7 -10 9 pfu/ml, total volume 300 l) in minimal essential medium (MEM; containing 0.1% BSA, 100 U/ml penicillin, and 100 g/ml streptomycin) for 30 min at 37°C. The rings were then transferred to fresh MEM and incubated for 24 h at 37°C in a CO 2 incubator (5% CO 2, Forma Scientific). The next day, the rings were suspended for isometric force recording in an organ chamber. The viral titer and incubation time were considered to be optimal for ex vivo gene transfer on the basis of results of our previous studies (5, 31) . Nontransduced arteries used as controls for certain experiments were incubated in MEM alone for 24 h.
Western blot analysis of recombinant iNOS. Vascular tissues were homogenized in cold lysis buffer [50 mmol/l Tris ⅐ HCl (pH 7.5), 0.1 mmol/l EDTA, 0.1 mmol/l EGTA, 0.1% SDS, 0.1% deoxycholate, 1% IGEPAL, and a cocktail of protease inhibitors; all from Sigma]. Total proteins were extracted by rotating the lysate for 1 h at 4°C. The sample was then centrifuged for 5 min at 14,000 g, and the supernatant was harvested. Protein concentrations were determined using an assay kit (Bio-Rad; Hercules, CA). Sample proteins (150 g/lane) were resolved on a 7.5% SDS-PAGE gel and transferred to nitrocellulose. Positive control was a lysate of mouse macrophages stimulated with interferon-␥ and lipopolysaccharide. Primary antibody was monoclonal anti-iNOS (N39120, BD Transduction; San Diego, CA). Chemiluminescence was used to visualize bands (ECL, Amersham; Arlington Heights, IL).
Immunohistochemical analysis of gene expression. Expression of recombinant iNOS was visualized by immunohistochemistry performed on rings 24 h after transduction. Sections (5 m) were cut from rings frozen in embedding medium (OCT compound). After tissue was dried onto the slide, it was acetone fixed and endogenous peroxidase blocked in PBS-0.1% sodium azide-0.3% H2O2. Standard methods with slight modifications were used. Blocking of nonspecific proteins was done in 0.5 M PBS with 0.5% Tween 20 and 10% normal rabbit serum. All antibodies were diluted in the same 0.5 PBS-Tween with 1% normal rabbit serum. Primary antibody was a monoclonal anti-iNOS (N39120, 1:50, BD Transduction) followed by a secondary biotinylated rabbit anti-mouse IgG (1:500). Samples were then incubated with peroxidase-conjugated streptavidin. Color was developed with 3-amino-9-ethycarbazole, and tissues were counterstained with hematoxylin. Antibody specificity of staining was confirmed by staining iNOS-transduced sections with an isotype-matched irrelevant antibody or without primary antibody.
Analysis of vascular reactivity. Twenty-four hours after gene transfer, rings were connected to an isometric forcedisplacement transducer (Grass FT03, Grass Instruments; Quincy, MA) and suspended in an organ chamber filled with 25 ml control solution (37°C, pH 7.4) aerated with 94% O2-6% CO2. Isometric tension was recorded continuously. The rings were allowed to stabilize at a resting tension of 0.2-0.4 g for 1 h. Each ring was then gradually stretched to the optimal point of its length-tension curve (ϳ3.0 g) as determined by the contraction to 10 Ϫ5 M UTP. All experiments were conducted in the presence of 10 Ϫ5 M indomethacin to eliminate the possible influence of endogenous cyclooxygenase. The incubation time with indomethacin or N G -nitro-L-arginine methyl ester (L-NAME; 3 ϫ 10 Ϫ4 M) was 30 or 15 min, respectively. To evaluate relaxation responses, the rings were contracted with median effective concentrations (EC 50) of UTP (3 ϫ 10 Ϫ6 -3 ϫ 10 Ϫ5 M) before the addition of agonists. Concentration-response curves were obtained in a cumulative fashion. Several rings prepared from the same artery were studied in parallel. The relaxations were expressed as a percentage of maximal relaxations induced by 3 ϫ 10 Ϫ4 M papaverine. Measurement of cGMP. A radioimmunoassay technique was used to determine the levels of cGMP, as reported previously (31) . Rings were initially incubated in MEM in a 5% CO 2 incubator at 37°C for 30 min. The rings were then removed from the medium and quickly frozen in liquid nitrogen. After homogenization, cGMP levels were measured by a cGMP radioimmunoassay kit (Amersham). Protein concentration was measured by a DC Protein Assay Kit (Bio-Rad). Rings taken from the same dogs were studied in parallel.
Quantification of vascular O 2 Ϫ ⅐ production. O 2 Ϫ ⅐ production was measured using lucigenin-enhanced chemiluminescence (30) . A low concentration of lucigenin (5 mol/l) was used to avoid the autooxidation of lucigenin (19) . Briefly, the basilar artery was cut into 4-mm segments. Rings were placed in a modified Krebs-HEPES buffer (pH 7.4) and equilibrated for 30 min at 37°C. Scintillation vials containing 1 ml Krebs-HEPES buffer with 5 mol/l lucigenin were placed into a scintillation counter (LS 5000, Beckman Instruments; Fullerton, CA) switched to the out-of-coincidence mode. After dark adaptation, background signals were recorded, and vascular rings were then added to the vial. For 4,5-dihydroxy-1,3-benzenedisulfonic acid (tiron) experiments, iNOS-transduced rings were incubated with tiron (10 Ϫ2 M) for 20 min before the recording. Photon counts were recorded every 2 min for 8 min, and the background was subtracted. The vessels were then dried for 24 h at 90°C and weighed. The results were expressed as counts per minute per milligram of dry weight.
Drugs. The following pharmacological agents were used: UTP, bradykinin, papaverine hydrochloride, L-NAME, indomethacin, tiron (Sigma), lucigenin (Molecular Probes; Eugene, OR), and diethylaminodiazen-1-ium-1,2-dioate (DEANONOate; Cayman Chemical, Ann Arbor, MI). Drugs were dissolved in distilled water. Solutions of DEA-NONOate in the highest concentration were prepared in 1.5 M Tris (pH 8.8). The concentrations of all drugs are expressed as the final moles per liter concentration in the control solution.
Statistical analysis. The results of this study are expressed as means Ϯ SE; n refers to the number of animals. The levels of cGMP and O 2 Ϫ ⅐ in each group were compared by factorial ANOVA. To compare the sensitivity to a vasomotor agent, the half-maximal effective concentrations (EC 50) were calculated by nonlinear regression and were expressed as Ϫlog M. The concentration-response curves were analyzed by repeated-measures ANOVA followed by Bonferroni-Dunn's post hoc test. Statistical significance was accepted at a P value of Ͻ0.05.
RESULTS
Expression and localization of recombinant protein.
Expression of recombinant iNOS (10 9 pfu/ml) protein was confirmed in iNOS-transduced basilar arteries by Western blot analysis. A representative blot is shown in Fig. 1 . Immunohistochemistry showed that recombinant iNOS was localized predominantly in the adventitial layer (Fig. 2C) . In contrast, control and ␤-Gal-transduced vessels did not show iNOS immuno-reactivity (Fig. 2, A and B) . Incubation of arteries with lower titers of adenovirus (10 7 and 10 8 pfu/ml) did not result in detectable expression of recombinant iNOS.
Concentration-dependent contraction to UTP. The concentration-response curve to UTP was significantly shifted to the right in iNOS (10 9 pfu/ml)-transduced rings (Fig. 3) . Maximal contraction to UTP was significantly potentiated in arteries transduced by iNOS (Table 1) . Gene transfer with lower titers of iNOS (10 7 and 10 8 pfu/ml) did not significantly affect vasomotor reactivity to UTP (Table 1) .
Endothelium-dependent relaxation to bradykinin. During contraction to UTP (3 ϫ 10 Ϫ6 -3 ϫ 10 Ϫ5 M), bradykinin (10 Ϫ10 -10 Ϫ6 M) caused endothelium-dependent relaxations. L-NAME (3 ϫ 10 Ϫ4 M) abolished relaxations to bradykinin (data not shown), suggesting that the effect of bradykinin was exclusively mediated by NO. The relaxations to bradykinin in iNOS (10 9 pfu/ml)-transduced vessels were significantly inhibited compared with control and ␤-Gal-transduced rings (Fig. 4) . Gene transfer with lower titers of iNOS (10 7 and 10 8 pfu/ml) did not significantly affect relaxations to bradykinin (Table 2) . Twenty-four hours of incubation with a 10 Ϫ2 M concentration of tiron did not improve impaired endothelium-dependent relaxations to bradykinin in iNOS-transduced arteries (33 Ϯ 5% and 7 Ϯ 15%, relaxation to 10 Ϫ6 bradykinin in iNOS and iNOS plus tiron arteries, respectively). Tiron did not affect relaxations to bradykinin in control and ␤-Gal-transduced arteries (71 Ϯ 8% and 68 Ϯ 12%, relaxation to 10 Ϫ6 M bradykinin for ␤-Gal and ␤-Gal plus tiron arteries, respectively; n ϭ 3 dogs).
Endothelium-independent relaxation to DEANONOate. During contractions to UTP (3 ϫ 10 Ϫ6 -3 ϫ 10 Ϫ5 M), DEA-NONOate (10 Ϫ10 -10 Ϫ5 M) caused concentration-dependent relaxations. The concentrationresponse curve to DEA-NONOate was significantly shifted to the right in iNOS (10 9 pfu/ml)-transduced rings (Fig. 5 ). Gene transfer with lower titers of iNOS (10 7 and 10 8 pfu/ml) did not significantly affect relaxations to DEA-NONOate (Table 3) .
Basal cGMP production. Basal production of cGMP was significantly increased in iNOS (10 9 pfu/ml)-transduced rings compared with control and ␤-Gal-transduced rings ( Fig. 6 ; P Ͻ 0.05, n ϭ 7).
O 2 Ϫ ⅐ production. Lucigenin-enhanced chemiluminescence showed a three-to fourfold higher basal O 2 Ϫ ⅐ level in AdiNOS (10 9 pfu/ml)-transduced rings compared with levels in control and AdLacZ-transduced rings ( Fig. 7 ; P Ͻ 0.05, n ϭ 4-9). Increased production of O 2 Ϫ ⅐ was inhibited in the presence of the O 2 Ϫ ⅐ scavenger tiron (10 Ϫ2 M).
DISCUSSION
This is the first study to examine the effect of recombinant iNOS on vasomotor function of cerebral arteries. After ex vivo gene transfer, morphological analysis indicated that iNOS was mostly expressed in adventitia. Expression of recombinant iNOS in canine cerebral arteries reduced contractions to UTP and attenuated relaxations to endogenous NO released from the endothelium as well as exogenous NO generated by DEANONOate. We also demonstrated that iNOS caused a significant increase in cGMP levels and superoxide anion production in transduced cerebral arteries.
Immunohistochemistry and Western blot analysis were employed to confirm expression and determine localization of recombinant iNOS. As in our previous ex vivo studies, expression of recombinant iNOS was mainly localized in adventitia (5, 25, 31) . Immunogold labeling and electron microscopy studies demonstrated that adventitial fibroblasts are very good target cells for expression of recombinant proteins (5, 31) . Under physiological conditions, the adventitia stabilizes the Data are expressed as means Ϯ SE; n ϭ no. of dogs. * P Ͻ 0.05 compared with control, AdLacZ, and lower titers of AdiNOS. Data are expressed as means Ϯ SE; n ϭ no. of dogs. Ad LacZ, adenoviral vector encoding the ␤-galactosidase gene; AdiNOS, adenoviral vector encoding the inducible nitric oxide synthase gene; pfu, plaque-forming units. * P Ͻ 0.05 compared with control, AdLacZ, and lower titers of AdiNOS. Fig. 4 . Endothelium-dependent relaxation to bradykinin was significantly impaired in arteries expressing iNOS (maximum relaxation ϭ 66.6 Ϯ 5.85% and 30.3 Ϯ 9.45% in AdLacZ-and AdiNOStransduced rings, respectively; P Ͻ 0.01, n ϭ 8). Data are shown as means Ϯ SE and are expressed as a percentage of the maximal relaxation induced by papaverine (3 ϫ 10 Ϫ4 M, 100% ϭ 4.05 Ϯ 0.508, 4.19 Ϯ 0.498, and 3.18 Ϯ 0.411 g for control, AdLacZ-transduced, and AdiNOS-transduced rings, respectively). vascular wall and serves to connect the blood vessel to surrounding tissue. However, in diseased arteries, adventitia can play an important role in pathogenesis of vascular dysfunction (9, 15) . It is interesting that cerebral arteries do not have an external elastic lamina that separates adventitia from the smooth muscle cells. This morphological feature may enable NO released from fibroblasts to travel even longer distances within the media of cerebral arteries.
The most striking finding of the present study is that both vasoconstrictor and vasodilator responses are blunted in arteries expressing recombinant iNOS in adventitia. The inhibitory effect of iNOS expression on vasoconstrictor effect is not surprising, and our findings are consistent with reported ability of recombinant iNOS to inhibit the contractile effects of phenylephrine and U-46619 (8) . This finding is best explained by the increase in cGMP content in the AdiNOS-transduced vascular wall. cGMP is a well-established second messenger and mediator of vasodilator effect of NO (23) , and high cGMP levels are to be expected in arteries transduced by iNOS (16) . Indeed, in our previous study (1), we reported an ϳ10-fold increase in cGMP levels in canine basilar arteries transduced with AdeNOS and treated with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX). It should be noted that, in the present study, cGMP was measured in the absence of IBMX, and this may explain the only threefold increase of cGMP detected in AdiNOStransduced arteries. It is interesting that the absolute value of the maximal contraction to UTP was significantly augmented in iNOS-transduced arteries. At the present time, we do not have an explanation for this observation.
High NO levels produced by iNOS may also provide an explanation for the reduced reactivity of smooth muscle cells to endogenous and exogenous NO. Our results are in agreement with those obtained using eNOS transgenic mice and iNOS gene transfer in the rabbit carotid artery (8, 24) . In both studies, chronic high production of NO in the arterial wall was associated with a reduced vasodilator effect of NO. It appears that the vascular system can adapt to a high local concentration of NO by downregulating the signal transduction mechanism responsible for mediation of NO-induced vasodilatation. The exact molecular mechanism underlying this adaptation after iNOS gene transfer remains to be clarified.
Besides high basal levels of cGMP in iNOS-transduced arteries, increased production of superoxide anions may provide an additional explanation for attenuation of endothelium-dependent relaxation mediated by NO and relaxation to DEA-NONOate. Inconsistent findings were reported in a previous attempt to normalize the vasomotor function of the iNOS-transduced carotid artery with superoxide dismutase (8) . This is most likely due to the fact that superoxide anion reacts with NO more rapidly than with superoxide dismutase (4) . Chemical antagonism between NO and superoxide is source of a potent oxidant, peroxynitrite, which can cause nitration of proteins, leading to irreversible alteration in function (2) . We have also been unable to normalize the vasomotor function of iNOS-transduced arteries by a superoxide anion scavenger, tiron.
The exact source of superoxide anions in AdiNOStransduced arteries is unknown. However, previous biochemical and pharmacological studies demonstrated that NOS itself could be a potent source of superoxide anions (35) . iNOS generates superoxide anions from the reductase domain. This is in contrast to Data are expressed as means Ϯ SE; n ϭ no. of dogs. DEANONOate, diethylaminodiazen-1-ium-1,2-dioate. * P Ͻ 0.05 compared with control, AdLacZ, and lower titers of AdiNOS.
the neuronal and endothelial isoforms of NOS, which generate superoxide mostly from the oxigenase domain (21) . Furthermore, iNOS-induced formation of superoxide anions occurs even in the presence of a high concentration of substrate, L-arginine (1 mM), whereas L-arginine can suppress production of superoxide anions by neuronal NOS or eNOS (35) . A recent study by Huisman and colleagues demonstrated that the oxigenase domain of iNOS may also be a source of superoxide anion (10) . Supplementation with a cofactor, tetrahydrobiopterin, reduced superoxide anion formation by iNOS, suggesting that suboptimal concentration of tetrahydrobiopterin may contribute to the iNOS-mediated production of superoxide anion (10). We did not measure tetrahydrobiopterin levels in arteries expressing recombinant iNOS, and further studies are needed to determine whether this mechanism may explain increased superoxide production in iNOS-transduced arteries.
A major limitation of the present study is that the exclusive expression of iNOS by adenovirus-mediated gene transfer in normal arteries is not associated with coexpression of coordinately regulated vascular genes (20) . Proinflammatory stimuli can upregulate expression of many proteins that are important for iNOS enzymatic activity or vascular effects of NO, including the L-arginine transporter and GTP cyclohydrolase I, the rate-limiting enzyme in biosynthesis of tetrahydrobiopterin (29) . It is interesting that ongoing phase I gene therapy clinical trials with iNOS have been designed to prevent coronary artery restenosis and occlusion of arterial-venous fistula (33) . In both applications, inhibition of smooth muscle cells proliferation and vascular remodeling (rather than normalization of vasomotor function) of diseased blood vessels are the major therapeutic goals. Obviously, a better understanding of the natural course of endogenous iNOS expression and its function in the diseased vascular wall may help to optimize current applications and develop new therapeutic indications of recombinant iNOS. Whether under certain circumstances iNOS gene transfer may be used in the prevention and treatment of cerebrovascular diseases remains to be determined.
Ex vivo gene transfer of iNOS to cerebral arteries results in expression of functional protein, mostly in adventitia. Increased production of cGMP and superoxide anions in iNOS-transduced arteries may explain the attenuation of vasomotor function. Whether these effects of recombinant iNOS may be beneficial (or detrimental) in the prevention and treatment of cerebrovascular diseases requires further improvement in understanding of iNOS vascular biology.
